CellCentric

CellCentric is a biotech company in Cambridge, United Kingdom. It has raised $340.0M across 2 rounds, most recently a $220.0M Series D in May 2026.

The p300/CBP inhibitor company

Headquarters
Cambridge
Employees
11–50
Total Funding
$340.0M
Last Round
$220.0M Series DMay 2026
Rounds
2

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 2 funding rounds and 1 investor for this company. The full record is or through the API.

About

CellCentric develops inobrodib to treat people living with multiple myeloma and other cancers. Its approach focuses on inhibiting the twin proteins p300 and CBP with a small molecule oral drug, drawing on research into cell fate control mechanisms. CellCentric collaborates with scientific and clinical centers and engages patients and patient-focused organizations to understand their needs and priorities.

Summary

It lists 11–50 employees. It has raised $340.0M in total across 2 rounds, most recently a $220.0M Series D round in May 2026. Investors include RA Capital Management.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Data from Indexed.vcUpdated
Series DSeries DMay 2026
$220.0M

Sign up to see all 2 events

Funding: Series C through Series D. Amounts, valuations, and investors where available.

Investors

Similar Companies

Paratek PharmaceuticalsAcquired

Paratek Pharmaceuticals develops and delivers innovative treatments for serious infectious diseas...

Boston, United States201–500Biotech, Healthcare
ConvertibleTotal funding$1.8BApr 2018
Sana BiotechnologyIPO

Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...

Seattle, United States201–500Biotech, Healthcare
Series DTotal funding$1.4BJun 2020
Abogen Biosciences

Abogen Biosciences develops RNA therapeutics using integrated mRNA design, lipid nanoparticle del...

Suzhou, China201–500Biotech, Drug Discovery
Extension RoundTotal funding$1.2BNov 2021
Alnylam PharmaceuticalsIPO

Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...

Cambridge, United States1001–5000Biotech, Genomics
Corporate RoundTotal funding$1.0BApr 2020
Tiantan Biological / China Biologic (泰邦生物集团)

China's leading blood products manufacturer

Beijing, China1001–5000Biotech, Healthcare
Growth EquityTotal funding$5.1BAug 2022
Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

CellCentric on Indexed.vc
<a href="https://indexed.vc/companies/cellcentric-cellcentric"><img src="https://indexed.vc/api/badge/company/cellcentric-cellcentric" alt="CellCentric on Indexed.vc" width="260" height="76" /></a>